(Q43237689)

English

A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate

scientific article published in December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Erik De Clercq

1

0 references

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

2935-2937

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

The history of antiretrovirals: key discoveries over the past 25 years

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™

1 reference

https://api.crossref.org/works/10.1517%2F14656560903418467

21 January 2018

Identifiers

10.1517/14656560903418467

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43237689&oldid=1984667538"